Menu
Search
|

Menu

Close
X

Catabasis Pharmaceuticals Inc CATB.OQ (NASDAQ Stock Exchange Global Market)

7.03 USD
-0.11 (-1.54%)
As of Jul 23
Previous Close 7.14
Open 7.15
Volume 9,709
3m Avg Volume 39,938
Today’s High 7.24
Today’s Low 6.87
52 Week High 9.76
52 Week Low 3.60
Shares Outstanding (mil) 22.48
Market Capitalization (mil) 55.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.623
FY18
-6.509
FY17
-12.800
FY16
-22.407
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
--
7.92
Price to Book (MRQ)
vs sector
2.60
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
19.07
14.56
LT Debt to Equity (MRQ)
vs sector
3.86
10.21
Return on Investment (TTM)
vs sector
-107.14
14.49
Return on Equity (TTM)
vs sector
-117.90
15.79

EXECUTIVE LEADERSHIP

Kenneth Bate
Co-Chairman of the Board, Since 2016
Salary: --
Bonus: --
Michael Ross
Co-Chairman of the Board, Since 2016
Salary: --
Bonus: --
Jill Milne
President, Chief Executive Officer, Co-Founder, Director, Since 2016
Salary: $462,264.00
Bonus: --
Deirdre Cunnane
Senior Vice President, General Counsel, Treasurer, Since 2016
Salary: --
Bonus: --
Andrew Nichols
Chief Scientific Officer, Since 2016
Salary: $346,800.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Kendall Sq Ste B14202
CAMBRIDGE   MA   02139-1573

Phone: +1617.3491971

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

SPONSORED STORIES